{"url_path":"/sec/mdt/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 Market for Medtronic’s Common Equity, Related Shareholder Matters, and Issuer Purchases of Equity Securities","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/1613103/0001628280-26-044354-index.html","accession_number":"0001628280-26-044354","cik":"0001613103","ticker":"MDT","issuer_name":"Medtronic plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1613103/0001628280-26-044354-index.html","primary_entity_key":"0001613103","primary_entity_name":"Medtronic plc"},"word_count":853,"has_tables":true,"body_markdown":"Item 5. Market for Medtronic’s Common Equity, Related Shareholder Matters, and Issuer Purchases of Equity Securities\n\nThe Company’s ordinary shares are listed on the New York Stock Exchange under the symbol “MDT.”\n\nThe following table provides information about the shares repurchased by the Company during the fourth quarter of fiscal year 2026:\n\nFiscal PeriodTotal Number of\nShares PurchasedAverage Price\nPaid per ShareTotal Number of Shares\nPurchased as a Part of\nPublicly Announced\nProgramMaximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program\n\n1/24/2026-2/20/20261,232,279 $97.40 1,232,279 $1,493,804,844 \n\n2/21/2026-3/27/20263,114,201 95.01 3,114,201 1,197,927,955 \n\n3/28/2026-4/24/2026164,623 86.19 164,623 1,183,739,350 \n\nTotal4,511,103 $95.34 4,511,103 $1,183,739,350 \n\nIn March 2024, the Company's Board of Directors authorized $5.0 billion for share repurchases. There is no specific time-period associated with these repurchase authorizations. For additional discussion, see Note 11 to the consolidated financial statements in “Item 8. Financial Statements and Supplementary Data” in this Annual Report on Form 10-K.\n\nOn June 12, 2026, there were approximately 17,816 shareholders of record of the Company’s ordinary shares. Ordinary cash dividends declared and paid totaled $0.71 per share for each quarter of fiscal year 2026 and $0.70 per share for each quarter of fiscal year 2025. On June 3, 2026, the Company announced an increase in Medtronic's cash dividends for the first quarter of fiscal year 2027, raising the amount to $0.72 per share.\n\nStock Performance Graph\n\nThe following graph compares the cumulative total shareholder return on Medtronic’s ordinary shares with the cumulative total shareholder return on the Standard & Poor’s (S&P) 500 Index and the S&P 500 Health Care Equipment Index for the last five fiscal years. The graph assumes that $100 was invested at market close on April 30, 2021 in Medtronic’s ordinary shares, the S&P 500 Index, and the S&P 500 Health Care Equipment Index and that all dividends were reinvested.\n\nCompany/IndexApril 2021April 2022April 2023April 2024April 2025April 2026\n\nMedtronic plc$100.00 $81.50 $73.42 $66.51 $72.57 $74.09 \n\nS&P 500 Index100.00 100.21 102.88 127.80 140.33 184.25 \n\nS&P 500 Health Care Equipment Index100.00 93.29 99.11 101.83 112.08 97.45 \n\nFor information on the Company's equity compensation plans, see \"Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters\" in this Annual Report on Form 10-K.\n\n29\n\n[Table of Conten](#i8ac9545bba26417b86662fb12ca4cf78_7)[ts](#i8ac9545bba26417b86662fb12ca4cf78_7)\n\nIrish Restrictions on Import and Export of Capital\n\nExcept as indicated below, there are no restrictions on non-residents of Ireland dealing in Irish domestic securities, which includes ordinary shares of Irish companies. Except as indicated below, dividends and redemption proceeds also continue to be freely transferable to non-resident holders of such securities. The Financial Transfers Act, 1992 provides that the Irish Minister for Finance can make provision for the restriction of financial transfers between Ireland and other countries. For the purposes of this Act, “financial transfers” include all transfers which would be movements of capital or payments within the meaning of the treaties governing the E.U. if they had been made between Member States of the E.U. To date, the Irish Minister for Finance has restricted financial transfers between Ireland and a number of third countries and the list is subject to on-going change.\n\nAny transfer of, or payment in respect of, a share or interest in a share involving the government of any country that is currently the subject of United Nations or E.U. sanctions, any person or body controlled by any of the foregoing, or by any person acting on behalf of the foregoing, may be subject to restrictions pursuant to such sanctions as implemented into Irish law.\n\nIrish Taxes Applicable to U.S. Holders\n\nDividends paid by Medtronic will generally be subject to Irish dividend withholding tax (currently at a rate of 25 percent) unless an exemption applies.\n\nDividends paid to U.S. residents will not be subject to Irish dividend withholding tax provided that:\n\n•in the case of a beneficial owner of Medtronic shares held in the DTC, the address of the beneficial owner in the records of his or her broker is in the United States and this information is provided by the broker to the Company’s qualifying intermediary; or\n\n•in the case of a record owner, the record owner has provided to the Company’s transfer agent a valid U.S. Certification of Residence (Form 6166) or valid Irish Non-Resident Form V2.\n\nIrish income tax may also arise with respect to dividends paid on Medtronic’s ordinary shares. A U.S. resident who meets one of the exemptions from dividend withholding tax described above and who does not hold Medtronic shares through a branch or agency in Ireland through which a trade is carried on generally will not have any Irish income tax liability on a dividend paid by Medtronic. In addition, if a U.S. shareholder is subject to the dividend withholding tax, the withholding payment discharges any Irish income tax liability, provided the shareholder furnishes to the Irish Revenue authorities a statement of the dividend withholding tax imposed.\n\nWhile the U.S./Ireland Double Tax Treaty contains provisions regarding withholding, due to the wide scope of the exemptions from dividend withholding tax available under Irish domestic law, it would generally be unnecessary for a U.S. resident shareholder to rely on the treaty provisions."}